Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Senti Biosciences, Inc. Director's Dealing 2026

Feb 3, 2026

34717_dirs_2026-02-03_4aaa93f4-1f86-4ed8-a77d-73a278568965.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Senti Biosciences, Inc. (SNTI)
CIK: 0001854270
Period of Report: 2026-02-02

Reporting Person: Lu Timothy K (Director, CEO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2026-02-02 Common Stock F 4191 Disposed 720249 Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 52839 Indirect
Common Stock 52839 Indirect

Footnotes

F1: Represents the number of shares of common stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of certain time-based restricted stock unit awards and does not represent an open market sale.

F2: The shares are held by Luminen Services, LLC, as trustee of the Luminen Trust, of which the reporting person is the settlor. The reporting person disclaims Section 16 beneficial ownership of the securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.